Mackenzie Financial
BCRX icon

Mackenzie Financial’s BioCryst Pharmaceuticals BCRX Stock Holding History

Mackenzie Financial’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.47M Buy
347,299
+103,883
+43% +$939K ﹤0.01% 922
2026
Q1 		$2.32M Buy
243,416
+92,688
+61% +$720K ﹤0.01% 891
2025
Q4 		$1.15M Buy
150,728
+21,411
+17% +$155K ﹤0.01% 1018
2025
Q3 		$982K Buy
129,317
+22,834
+21% +$190K ﹤0.01% 1067
2025
Q2 		$954K Sell
106,483
-9,775
-8% -$91K ﹤0.01% 1020
2025
Q1 		$872K Buy
116,258
+31,596
+37% +$255K ﹤0.01% 1017
2024
Q4 		$637K Buy
84,662
+55,535
+191% +$422K ﹤0.01% 1075
2024
Q3 		$221K Buy
29,127
+1,214
+4% +$9.23K ﹤0.01% 1340
2024
Q2 		$173K Sell
27,913
-4,344
-13% -$24K ﹤0.01% 1367
2024
Q1 		$164K Buy
32,257
+8,818
+38% +$49.6K ﹤0.01% 1374
2023
Q4 		$140K Buy
23,439
+10,026
+75% +$58.1K ﹤0.01% 1375
2023
Q3 		$86.1K Sell
13,413
-38,669
-74% -$278K ﹤0.01% 1363
2023
Q2 		$367K Sell
52,082
-6,798
-12% -$54.6K ﹤0.01% 1110
2023
Q1 		$491K Buy
58,880
+37,520
+176% +$361K ﹤0.01% 1033
2022
Q4 		$245K Sell
21,360
-31,227
-59% -$389K ﹤0.01% 1155
2022
Q3 		$663K Buy
52,587
+28,931
+122% +$372K ﹤0.01% 878
2022
Q2 		$250K Buy
23,656
+5,850
+33% +$60.3K ﹤0.01% 1172
2022
Q1 		$290K Buy
+17,806
New +$286K ﹤0.01% 1133
2021
Q4 		– Sell
-10,423
Closed -$150K – 1439
2021
Q3 		$150K Buy
+10,423
New +$164K ﹤0.01% 1354

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Mackenzie Financial's BCRX Position: Q2 2026 in Review

Mackenzie Financial increased its BioCryst Pharmaceuticals (BCRX) stake by 43% in Q2 2026, buying an estimated $939K and bringing the position to 347,299 shares worth $3.47M. The position accounts for ﹤0.01% of the portfolio, ranked #922.

Mackenzie Financial first reported a position in BCRX in Q3 2021 and has held it in 19 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Mackenzie Financial held 347,299 shares of BioCryst Pharmaceuticals worth $3.47M as of Q2 2026.
  • Mackenzie Financial bought 103,883 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $939K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Mackenzie Financial's portfolio in Q2 2026, its #922 holding.
  • Mackenzie Financial first reported a position in BioCryst Pharmaceuticals in Q3 2021 and has held it in 19 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.